Korea Q2 Roundup: Hanmi Dispute Simmers, Emerging Obesity Focus

As it reported mixed second-quarter earnings, South Korea's pharma industry is increasingly turning to obesity pipeline assets. Meanwhile, leadership disputes among family members within Hanmi are resurfacing.